Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 19, 2019
VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26
TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present new data on the potential ...
February 19, 2019
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 19, 2019
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
NEWARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired ...
February 19, 2019
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
February 19, 2019
electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies
BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education ...
February 19, 2019
Pfenex Announces FDA Acceptance of NDA for PF708
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
February 19, 2019
Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26
DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ...
February 19, 2019
Equillium to Host Business Update Call on February 26
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a ...
February 19, 2019
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer
AUSTIN, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s ...
February 19, 2019
Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
HOPKINTON, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
February 14, 2019
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
SALT LAKE CITY, Feb. 14, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated ...
February 14, 2019
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
BUFFALO, N.Y., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
February 14, 2019
TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer
SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced encouraging preliminary results from ...
February 14, 2019
Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
February 14, 2019
Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019
CRANBURY, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal ...
February 14, 2019
Inspire Medical Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative ...
February 14, 2019
CorMedix Inc. Announces FDA Meeting Update
BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
February 14, 2019
Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug ...
February 14, 2019
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug ...
February 14, 2019
Richard Brudnick to Join InflaRx Board of Directors
JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that ...
Page 12 of 138